Skip to main content
padlock icon - secure page this page is secure

Open Access TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells

Download Article:
(HTML 42.9 kb)
(PDF 581.9 kb)
The tripartite motif-containing protein 11 (TRIM11), a member of the TRIM protein family, has attracted much attention because of its involvement in the development of the central nervous system. It has gained renewed focus because of its newly found function in promoting tumors. However, little is known about its role in hepatocellular carcinoma (HCC). In the present study, we found TRIM11 to be overexpressed in HCC tissues and cell lines. Downregulation of TRIM11 inhibited HCC cell proliferation and invasion in vitro and in vivo as well as suppressed the epithelial‐mesenchymal transition (EMT) process. In addition, downregulation of TRIM11 decreased the protein expression levels of p-PI3K and p-Akt in HCC cells and thus inhibited activation of the PI3K/Akt signaling pathway. Based on these results, we suggest the importance of TRIM11 in HCC progression and the potential of TRIM11 as a therapeutic target for HCC.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Epithelial‐mesenchymal transition (EMT); Hepatocellular carcinoma (HCC); Invasion; Proliferation; Tripartite motif-containing protein 11 (TRIM11)

Document Type: Research Article

Affiliations: 1: Department of Abdominal Surgery, Zhejiang Cancer Hospital, Hangzhou, P.R. China 2: Department of Integrated Chinese and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, P.R. China 3: Zhejiang Institute for Food and Drug Control, Hangzhou, P.R. China 4: Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, P.R. China

Publication date: May 24, 2017

This article was made available online on December 15, 2016 as a Fast Track article with title: "TRIM11 Upregulation contributes to proliferation, invasion and EMT of hepatocellular carcinoma cells".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more